NEW YORK / Nov 08, 2023 / Business Wire / DocGo, a leading provider of technology-enabled mobile health services (Nasdaq: DCGO), today announced that the company will be participating in the following investor conferences during the month of November.
Needham & Company 4th Annual Tech Week
November 15, 2023 – Virtual 1x1 investor meetings, contact your Needham representative for additional information.
Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum
November 16, 2023 – 1x1 investor meetings, contact your Canaccord representative for additional information.
BTIG Digital Health Forum
November 20, 2023 – Virtual 1x1 investor meetings, contact your BTIG representative for additional information.
About DocGo
DocGo is leading the proactive health care revolution with an innovative care delivery platform that includes mobile health services, remote patient monitoring, and ambulance services. DocGo disrupts the traditional four-wall healthcare system by providing high quality, highly accessible care to patients where and when they need it. DocGo's proprietary technology and dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks, and health insurance providers. With mobile health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient's home or workplace. Together with DocGo's integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit www.docgo.com.
Last Trade: | US$1.63 |
Daily Change: | 0.005 0.31 |
Daily Volume: | 121,530 |
Market Cap: | US$158.940M |
August 07, 2025 August 06, 2025 May 08, 2025 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load